Get the Stockscreener App
1.33
5.56%
0.07
After Hours:
1.33
Century Therapeutics Inc stock is traded at $1.33, with a volume of 555.65K.
It is up +5.56% in the last 24 hours and down -14.19% over the past month.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
See More
Previous Close:
$1.26
Open:
$1.26
24h Volume:
555.65K
Relative Volume:
1.55
Market Cap:
$106.74M
Revenue:
$2.24M
Net Income/Loss:
$-136.67M
P/E Ratio:
-0.6129
EPS:
-2.17
Net Cash Flow:
$-102.08M
1W Performance:
-2.21%
1M Performance:
-14.19%
6M Performance:
-56.11%
1Y Performance:
-24.43%
1-Day Range:
$1.25
$1.43
1-Week Range:
$1.14
$1.43
52-Week Range:
$1.14
$5.51
Century Therapeutics Inc Stock (IPSC) Company Profile
Name
Century Therapeutics Inc
Sector
Industry
Phone
215-981-4000
Address
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-27-22 | Initiated | Chardan Capital Markets | Buy |
| Oct-31-22 | Initiated | Guggenheim | Buy |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| May-23-22 | Initiated | H.C. Wainwright | Buy |
| May-12-22 | Initiated | William Blair | Mkt Perform |
| Jul-13-21 | Initiated | BofA Securities | Buy |
| Jul-13-21 | Initiated | JP Morgan | Overweight |
| Jul-13-21 | Initiated | Piper Sandler | Overweight |
View All
Century Therapeutics Inc Stock (IPSC) Latest News
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates - The Manila Times
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition - The Manila Times
Ichnos Glenmark Innovation (IGI) Announces First Presentation of Data from Phase 1 Study of the Trispecific ISB 2001 in Relapsed/Refractory Multiple Myeloma (r/rMM) at Upcoming ASH Annual Meeting - The Manila Times
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of - The Bakersfield Californian
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting - Yahoo Finance
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences - The Manila Times
Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference - Yahoo Finance
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate - Yahoo Finance
electroCore (ECOR) Stock Jumps 11.7%: Will It Continue to Soar? - Yahoo Finance
Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 6.4% in September - MarketBeat
As the Cell Therapy Market Eyes $48 Billion, Bayer Invests $215 Million in Century Therapeutics As Revealed... - WhaTech
Dimensional Fund Advisors LP Acquires New Shares in Zai Lab Limited (NASDAQ:ZLAB) - Defense World
Artiva, Century, others extend natural-killer autoimmune push - BioWorld Online
Ubiquiti Inc. (NYSE:UI) Shares Sold by Dimensional Fund Advisors LP - Defense World
American Century Companies Inc. Has $128,000 Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
American Century Companies Inc. Acquires 36,528 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
American Century Companies Inc. Boosts Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World
American Century Companies Inc. Purchases Shares of 9,803 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
American Century Companies Inc. Increases Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
American Century Companies Inc. Cuts Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
American Century Companies Inc. Has $291,000 Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) - Defense World
American Century Companies Inc. Decreases Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by American Century Companies Inc. - MarketBeat
American Century Companies Inc. Increases Stock Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) - Defense World
American Century Companies Inc. Boosts Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
American Century Companies Inc. Sells 36,820 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
You might want to take a look at Century Therapeutics Inc (IPSC) now - SETE News
Market Watch: Century Therapeutics Inc (IPSC)’s Noteworthy Drop, Closing at 1.61 - The Dwinnex
American Century Companies Inc. Has $687,000 Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Regenerative Medicine Market to Reach $37.27 Billion by 2031, Driven by the Growing Number of New Regenerative Medicine Approvals and Consistent Advancements in the Regenerative Medicine SpaceExclusive Report by Meticulous Research - The Malaysian Reserve
Taking a Closer Look At Century Therapeutics Inc (IPSC) Following Its Recent Trade - Knox Daily
Odyssey Therapeutics Appoints Timothy P. Walbert and Ian F. Smith to its Board of Directors - citybiz
New Century Financial Group LLC Sells 349 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - Defense World
What was Century Therapeutics Inc (IPSC)’s performance in the last session? - US Post News
Odyssey Therapeutics Appoints Biopharma Veterans Timothy P. Walbert and Ian F. Smith to its Board of Directors - Business Wire
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by American Century Companies Inc. - Defense World
American Century Companies Inc. Has $797,000 Stock Position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
American Century Companies Inc. Grows Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
American Century Companies Inc. Grows Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
American Century Companies Inc. Increases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
Short Interest in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Drops By 14.6% - Defense World
Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Bought by American Century Companies Inc. - MarketBeat
Century Therapeutics Announces Strategic Leadership Appointments - MSN
Century Therapeutics appoints new CFO and CSO By Investing.com - Investing.com Australia
Century names CFO, CSO - BioCentury
Century Therapeutics add two new members to its C-suite - The Business Journals
Century Therapeutics Appoint Morgan Conn, Ph.D., as CFO and Chad Cowan, Ph.D., as CSO - citybiz
Century Therapeutics (NASDAQ:IPSC) & BioAtla (NASDAQ:BCAB) Financial Comparison - Defense World
Century Therapeutics Appoints Morgan Conn as New CFO - TipRanks
Century Therapeutics Names Morgan Conn Chief Financial Officer - MarketWatch
Century Therapeutics Inc Stock (IPSC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Century Therapeutics Inc Stock (IPSC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Quimi Daphne | Director |
Sep 12 '24 |
Buy |
1.53 |
5,000 |
7,657 |
5,000 |
| Farid Adrienne | Chief Operations Officer |
Aug 05 '24 |
Sale |
1.83 |
1,073 |
1,960 |
136,163 |
| Carr Douglas | SVP Finance & Operations |
Aug 05 '24 |
Sale |
1.83 |
289 |
528 |
334,041 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):